SCHEMBL5148946

SCHEMBL5148946

CC(C)n1nc(-c2nc(OCCc3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
GSK3B P49841 1/20 0.37
SRC P12931 3/20 0.36
ABL1 P00519 2/20 0.36
HRH3 Q9Y5N1 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA3 P34903 1/20 0.34
PDE4A P27815 3/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
PIK3CD O00329 1/20 0.34
EGFR P00533 1/20 0.34
HCK P08631 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148967 0.96 HRH3 (0.36) GSK3BSRCABL1HRH3GABRA1
SCHEMBL5149200 0.90 SRC (0.43) SRCABL1PIK3CDEGFRHCK
SCHEMBL5149085 0.90 SRC (0.38) SRCABL1HRH3PIK3CDEGFR
SCHEMBL5149212 0.89 SRC (0.40) SRCABL1HRH3HCKFGFR1
SCHEMBL5152824 0.89 MPO (0.38) SRCABL1HRH3PIK3CDEGFR
SCHEMBL5152714 0.89 SRC (0.38) SRCABL1HRH3PDE4DPIK3CD
SCHEMBL5152823 0.87 ADORA2A (0.41) HRH3ADORA2AFGFR1FGFR2FGFR3
SCHEMBL5149124 0.87 PKM (0.41) SMN1; SMN2GSK3BHRH3GABRA1GABRG2
SCHEMBL5147947 0.87 HRH3 (0.34) SRCABL1HRH3ADORA2AFGFR1
SCHEMBL5150959 0.84 FGFR1 (0.39) SMN1; SMN2SRCABL1PIK3CDEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 SMN1; SMN2 1645/4885GSK3B 688/4885SRC 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.